Translation of pharmacogenetics to clinical practice: what will it take?

Slaughter, Richard L.

doi:10.1586/ecp.11.77

Cited by 6 publications

(3 citation statements)

References 14 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although clinicians and patients are generally positively disposed to the concept of personalised medicine, the introduction of personalised approaches will require a profound change in prescribing practice, with treatment decisions taken out of the hands of clinicians and patients and devolved to algorithms based on genetic tests or other biomarkers. This represents a growing challenge for medical education, if future generations of doctors are to be prepared for advances in the field (Slaughter 2012).…”

Section: Obstacles To Personalised Medicine and Pharmacogenetic Testimentioning

confidence: 99%

Personalised approaches to pharmacotherapy for schizophrenia

Lally

MacCabe

2016

BJPsych advances

View full text Add to dashboard Cite

SummaryThe traditional approach to selecting antipsychotic medication involves little more than trial and error. Recent advances in genetics and molecular science offer the hope of a ‘personalised medicine’ approach to antipsychotic development and prescribing in schizophrenia. Personalised medicine is the practice of tailoring medical treatment to the individual characteristics of each patient. In schizophrenia, this will involve the identification of more homogeneous subsets of patients through the application of genetics, epigenetics, proteomics and metabolomics, neuroimaging and other biomarkers, and the use of these findings to stratify patients according to their response to treatment. In this article, we focus on the emerging evidence in pharmacogenetics and biomarkers for assessing individual response and tolerability of antipsychotic medication in schizophrenia.

show abstract

Section: Obstacles To Personalised Medicine and Pharmacogenetic Testimentioning

confidence: 99%

Personalised approaches to pharmacotherapy for schizophrenia

Lally

MacCabe

2016

BJPsych advances

View full text Add to dashboard Cite

show abstract

“…However, evidence also exists that suggest it is of little clinical relevance. Despite this conflicting evidence, the Food and Drug Administration (FDA) has approved more than 100 drugs with pharmacogenetic information included within their labels [2]. There is a multitude of pharmacogenetic tests available to identify genes that may affect drug metabolism.…”

mentioning

confidence: 99%

“…Although the implementation of pharmacogenetics into routine practice is not occurring at the rate it was expected to, it is a maturing field that is being integrated into the practice of medicine more each day [2]. The future of pharmacogenetics and its place in clinical practice is still unclear, but there is the potential for individuals to be broadly genotyped and that their genetic information will guide therapy decisions throughout their lifetime [4].…”

mentioning

confidence: 99%